Evidence map›Paper›PMID 35023322›Full record

ArticleMolecular genetics & genomic medicine2022

Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk-reducing surgeries in BRCA mutation carriers.

Mahtab Vasigh, Bita Eslami, Ahmad Elahi, Ahmad Kaviani, Reza Shirkoohi, Keivan Majidzadeh, Newsha Nazarian, Ramesh Omranipour

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Mahtab VasighBreast Disease Research Center, Cancer Institute,Tehran University of Medical Sciences, Tehran, Iran.
Bita EslamiBreast Disease Research Center, Cancer Institute,Tehran University of Medical Sciences, Tehran, Iran.
Ahmad ElahiDepartment of Surgery, Alborz University of Medical Sciences, Karaj, Iran.
Ahmad KavianiBreast Disease Research Center, Cancer Institute,Tehran University of Medical Sciences, Tehran, Iran.
Reza ShirkoohiDepartment of Molecular Genetics, Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Keivan MajidzadehBreast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Newsha NazarianTehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
Ramesh OmranipourBreast Disease Research Center, Cancer Institute,Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-4785-281X
Motamed Cancer Institute · IRAcademic Center for Education, Culture and Research · IRIslamic Azad University Medical Branch of Tehran · IRJahrom University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA higher risk for breast and ovarian cancer has been reported in BRCA carriers and prophylactic surgeries are proposed to reduce this risk. This retrospective cohort study has evaluated the indication of BRCA1/2 genetic tests in Iranian women and the rate of women's acceptance of prophylactic surgeries recommended by the surgeon.

methodsMedical records of 147 high-risk women according to NCCN clinical practice guidelines who referred for BRCA mutations testing were assessed. Individual information, indications for BRCA1/2 genetic testing and their results, physician recommendations, and type of accepted surgery were registered. To evaluate the current status of women an active visit follow-up every six months was conducted.

resultsThe mean age of women was 43.40 ± 10.94 and the median follow-up time was 1.92 years. Genetic test results showed 49(33.3%) women were positive for either BRCA1/2 mutations. Although the occurrence of breast cancer younger than 40 was the most common indication for genetic tests (26.5%), positive breast cancer history in first-degree relatives and two relatives younger than 50 was the most common indications with positive results. The rate of acceptance of prophylactic mastectomy and bilateral salpingo-oophorectomy was (14.3% and 34.7%) in BRCA mutation carriers.

conclusionIf the onset of breast cancer at a young age (less than 40) will be the only indication for a BRCA analysis, the rate of a positive result (12.8%) is very low. Further studies are warranted to evaluate the age limit for genetic testing in our country. Prophylactic mastectomy acceptance is very low in BRCA1/2 carriers in our centers.

Indexed as

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsAdultFemaleGenetic TestingHumansIranMastectomyMiddle AgedMutationRetrospective StudiesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA1BRCA2breast cancergenesprophylactic surgical procedures

Identifiers

PMID35023322
PMCPMC8830810
OpenAlexW4205554531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.